RxDoctor Payments Data

Sukhvir Atwal, MD

Nephrology · Fresno, CANPI 1669685251

Payments from drug & device makers

$780in general payments, 2019–2025

Across 46 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$416
  • Fresenius USA Marketing, Inc.$69
  • AstraZeneca$62
  • GSK$52
  • Shire North American Group Inc$46
  • Novartis$30
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$76598%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$780 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$496,523
Medicare patients
880
Services billed
13,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide61$207,092
FarxigaDapagliflozin Propanediol73$80,119
JardianceEmpagliflozin54$69,475
VeltassaPatiromer Calcium Sorbitex35$58,866
LokelmaSodium Zirconium Cyclosilicate39$50,628
KerendiaFinerenone33$39,476
ProsolParenteral Amino Acid 20% No.1134$26,487
Sevelamer Carbonate98$22,464
Cinacalcet Hcl13$14,355
DapagliflozinDapagliflozin Propanediol20$12,225
Calcium Acetate66$5,485
Nifedipine ErNifedipine21$1,437
Calcitriol57$1,120
Tacrolimus14$1,057
Losartan Potassium93$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$69$207,09261 claims
AstraZenecaFarxiga, Lokelma$62$130,747112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,341 nephrology providers in California.

Other nephrology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →